Journal of translational medicine · 2026
Umbilical cord-derived mitochondrial transplantation restores tendon structure and function in a preclinical model of achilles tendinopathy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Da-Yoon, Kim Mi Jin, Park Min-Jeong, Lim Mina, Back Eun-Seo, Yun Chang-Koo, Kim Seong Hun, Kwon Hyuk Nam, Lee Chaeyoung, Min Kyunghoon, Choi Yong-Soo
Аннотация
BACKGROUND: Achilles tendinopathy is a degenerative musculoskeletal disorder for which disease-modifying therapies remain limited, largely due to the inability of current interventions to directly restore cellular bioenergetic function. Emerging evidence has identified mitochondrial dysfunction as a central contributor to tendon degeneration, highlighting mitochondria as a potential therapeutic target. Here, we evaluated umbilical cord-derived mitochondria (UC-MT) as a dose-defined, cell-free therapeutic strategy for tendinopathy.
METHODS: UC-MT were isolated from human umbilical cord-derived mesenchymal stem cells and characterized for mitochondrial integrity and bioenergetic activity. Therapeutic efficacy was evaluated in vitro using TNF-α-induced human tenocyte injury models and in vivo in a collagenase-induced rat model of Achilles tendinopathy. Dose-response effects were systematically assessed (5, 10, and 20 µg), and mitochondrial function, metabolic profiles, extracellular matrix remodeling, and functional recovery were analyzed using integrated molecular, histological, and functional assays, including transcriptomic and metabolomic profiling.
RESULTS: UC-MT treatment significantly restored mitochondrial membrane potential, ATP production, and respiratory complex activity in injured tenocytes, accompanied by attenuation of inflammatory signalling. Among the tested doses, 10 µg UC-MT consistently produced the most robust therapeutic effects across mitochondrial, metabolic, and structural outcome measures. In vivo, UC-MT administration improved tendon histoarchitecture, collagen organization, and functional performance, while integrated multi-omics analyses revealed coordinated metabolic reprogramming, including restoration of mitochondrial complex I-linked bioenergetic pathways.
CONCLUSIONS: Taken together, these findings position UC-MT as a dose-defined, cell-free therapeutic modality with translational potential for tendon regeneration. By directly targeting mitochondrial dysfunction, UC-MT restores mitochondrial bioenergetics and supports tendon regeneration in preclinical models of tendinopathy.
METHODS: UC-MT were isolated from human umbilical cord-derived mesenchymal stem cells and characterized for mitochondrial integrity and bioenergetic activity. Therapeutic efficacy was evaluated in vitro using TNF-α-induced human tenocyte injury models and in vivo in a collagenase-induced rat model of Achilles tendinopathy. Dose-response effects were systematically assessed (5, 10, and 20 µg), and mitochondrial function, metabolic profiles, extracellular matrix remodeling, and functional recovery were analyzed using integrated molecular, histological, and functional assays, including transcriptomic and metabolomic profiling.
RESULTS: UC-MT treatment significantly restored mitochondrial membrane potential, ATP production, and respiratory complex activity in injured tenocytes, accompanied by attenuation of inflammatory signalling. Among the tested doses, 10 µg UC-MT consistently produced the most robust therapeutic effects across mitochondrial, metabolic, and structural outcome measures. In vivo, UC-MT administration improved tendon histoarchitecture, collagen organization, and functional performance, while integrated multi-omics analyses revealed coordinated metabolic reprogramming, including restoration of mitochondrial complex I-linked bioenergetic pathways.
CONCLUSIONS: Taken together, these findings position UC-MT as a dose-defined, cell-free therapeutic modality with translational potential for tendon regeneration. By directly targeting mitochondrial dysfunction, UC-MT restores mitochondrial bioenergetics and supports tendon regeneration in preclinical models of tendinopathy.